A panelist discusses how a woman aged 77 years with bilateral neovascular age-related macular degeneration (nAMD) demonstrated different responses to treatments between her eyes, showing a superior response to faricimab in her right eye compared with ranibizumab, highlighting how some patients may respond better to specific anti-VEGF agents.
A panelist discusses how a man aged 79 years with long-duration diabetes and treatment-naive diabetic macular edema (DME) responded well to aflibercept 8-mg therapy, progressing from 4-week loading doses to an extended 10-week interval with resolution of macular edema and improved vision from 20/60 to 20/30.
A panelist discusses how a woman aged 74 years with neovascular age-related macular degeneration (nAMD) showed improved disease control and vision in her right eye after switching from ranibizumab to a high-dose aflibercept (8 mg) treatment that successfully extended intervals to 10 weeks.
